



BCR Online

Friday 19 March 2021

Programme



Organisation

Scientific Organiser

Peggy Jacques
UZ Gent
Peggy.Jacques@UGent.be

Congress Secretariat

Medicongress Services
Noorwegenstraat 49
B-9940 Evergem, Belgium
Phone: +32 (0)9 218 85 81
reumato@medicongress.com
www.medicongress.com



Welcome Address

Dear Colleagues,

On behalf of the Royal Belgian Society of Rheumatology (KBVR-SRBR), we are pleased to welcome you to the first-ever online edition of the **Belgian Congress on Rheumatology**.

This virtual congress will take place on **Friday 19 March 2021**.

Much to our regret it will not be possible to meet in person, but we are happy to be able to propose an interesting online programme consisting of invited talks, oral presentations and Updates in Therapeutics.

In addition to the scientific programme, a virtual exhibition and poster area will be available. There will be ample time for visiting the virtual booths, the online posters and for networking.

Together with the KBVR-SRBR board members, we hope you will enjoy this first virtual edition of the **Belgian Congress on Rheumatology** and remain,

Yours faithfully,

Peggy Jacques
Scientific President

Morning Programme

- 08.45 **Welcome and Opening Ceremony**
Valérie Badot, President KBVR-SRBR
Catherine Bailleux, Association Manager &
Jorien Geukens, Office & Project Assistant, KBVR-SRBR
Peggy Jacques, Scientific Organiser
- 09.10 **FWRO/FRSR Award Ceremony**
René Westhovens (KUL)
- Morning Programme – Part I**
Chairs: Laurent Méric de Bellefon (CNDG, CHU Saint-Pierre Brussels, UCL)
& Patrick Verschueren (KUL)
- 09.20 **Keynote Lecture**
From clinical trials to clinical practice: A good match?
Josef Smolen (Austria)
- Young Investigators' Meeting – Part I**
- 09.45 **Axial involvement in early peripheral spondyloarthritis: A prospective MRI study (YIM 1)**
Thomas Renson (UGent, VIB)
- 09.55 **Immunoglobulin G antibodies to three novel peptides in early axial spondyloarthritis in two independent cohorts (YIM 2)**
Pieter Ruytinx (UHasselt)
- 10.05 **Interleukin-23 inhibitors and their apparent ineffectiveness in the treatment of axial spondyloarthritis: A systematic review with meta-analysis (YIM 3)**
Louise Vanhoutte (KUL)
- 10.15 **Synovial tissue histopathology findings in early RA – Is it useful? Analysis of the Belgian CAP48 cohort**
Stéphanie de Montjoye (UCL, IREC)
- 10.25 **Update in Therapeutics – Organised with an educational grant from AbbVie**
The importance of achieving remission in RA
René Marc Flipo (France)

Morning Programme

- 10.40 **Update in Therapeutics – Organised with an educational grant from UCB**
Uveitis in axSpA
Irene van der Horst (The Netherlands)
- 10.55 Coffee break and Visit of the Exhibition
- Morning Programme – Part II**
Chairs: Yves Piette (UGent, AZ Sint-Jan Brugge) & Olivier Malaise (ULg)
- Abstract Presentations**
- 11.20 **Long-term effectiveness of methotrexate with step down glucocorticoids (COBRA Slim) versus other conventional DMARD regimens as initial RA therapy: 5-year outcomes of the CareRA trial (O1)**
Veerle Stouten (KUL)
- 11.30 **Spinal magnetic resonance imaging lesions in healthy subjects compared to axial spondyloarthritis patients (O2)**
Manouk de Hooze (UGent, VIB)
- 11.40 **Should we use bioDMARDs in first intention in early Rheumatoid Arthritis? Results at 5 years from the ERA Louvain Brussels cohort (O3)**
Emilie Sapart (UCL)
- 11.50 **Patients with early rheumatoid arthritis considered to have a favourable risk profile and treated according to a step-up strategy have an increased risk of chronic analgesic consumption (O4)**
Sofia Pazmino (KUL)
- 12.00 **Novel autoantibody biomarkers for the prediction of response to first-line combination therapy in rheumatoid arthritis (O5)**
Patrick Vandormael (UHasselt)
- 12.10 **Interplay between Treg and iNKT cells reveals a marked tissue tropism of immune regulatory networks in combined gut and joint inflammation (O6)**
Koen Venken (VIB, UGent)

Morning Programme

- 12.20 **Update in Therapeutics – Organised with an educational grant from Sanofi**
Update on RA and Diabetes
Philip Remans (Reumacentrum Genk)
- Thieves Market**
- 12.35 **Hydroxychloroquine use not so harmless: Little reminder from a clinical case (07)**
Tracy Vandergraesen (ULB)
- 12.45 **Treating cancer and associated “paraneoplastic” dermatomyositis with immune checkpoint inhibitor, a false good idea? (08)**
Florane Chauveheid (ULg)
- 12.55 **Clinical case: Systemic lupus erythematosus mimicry after viral infection with Coxsackie B4 (09)**
Julie Terrasson (KUL)
- 13.05 Lunch Break, Visit of the Exhibition and Poster Viewing

Afternoon Programme

Afternoon Programme - Part I

Chairs: Barbara Neerinckx (KUL) & Filip Van den Bosch (UGent)

Young Investigators' Meeting - Part II

- 14.00 **Laser Speckle Contrast Analysis (LASCA) in rheumatoid arthritis (YIM 5)**
Michaël Vanden Bulcke (UGent)
- 14.10 **The FLARE-RA questionnaire can identify OMERACT flares in patients with rheumatoid arthritis included in the TapERA trial (YIM 6)**
Delphine Bertrand (KUL)
- 14.20 **May capillaroscopy be a candidate tool in future algorithms for SSc-ILD: Are we looking for the holy grail? A systematic review (YIM 7)**
Amber Vanhaecke (Ugent)
- 14.30 **Epitope mapping of MDA5 using patient plasma derived autoantibodies (YIM 8)**
Eveline Van Gompel (Karolinska Institute, KUL)
- 14.40 **Update in Therapeutics – Organised with an educational grant from Galapagos**
Evolution of a JAK inhibitor: From bench to bedside
Peter Taylor (UK)
- 14.55 **Update in Therapeutics – Organised with an educational grant from Celltrion**
Novel opportunities with Infliximab in rheumatic diseases
René Westhovens (KUL)
- 15.10 **Update in Therapeutics – Organised with an educational grant from Roche**
Current and future treatments for GCA
Daniel Blockmans (KUL)
- 15.25 Coffee Break and Visit of the Exhibition

Afternoon Programme

Afternoon Programme - Part II

Chairs: Pascale Volders (ReumaClinic Genk) & Adrien Nzeusseu (UCL)

- 15.45 **Year in review - Clinical and Basic Science**
Gaëlle Varkas (UGent) and Eric Gracey (VIB, UGent)

Abstract Presentations

- 16.15 **Incidence and prevalence of systemic sclerosis associated interstitial lung disease in Flanders: A 12-years multicentre prospective cohort study (O10)**
Vanessa Smith (UGent)
- 16.25 **Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis (O11)**
Farah Tamirou (UCL)
- 16.35 **Serum IgG-undergalactosylation profiles reflect cumulative exposure to systemic inflammation in spondyloarthritis patients (O12)**
Ann-Sophie De Craemer (UGent, VIB)
- 16.45 **The use of disease activity indicators for rheumatoid arthritis in Belgian daily clinical practice (O13)**
Emma Buckinx (KUL)
- 16.55 **Unmasking the role of salivary gland involvement in anti-SSA positive patients (O14)**
Liselotte Deroo (UGent)
- 17.05 **Systematic analysis of Covid-19 infections and symptoms in systemic lupus erythematosus population: Correlation with disease severity and treatments (O15)**
Olivier Malaise (ULg)
- 17.15 **Keynote Lecture**
Infection prevention and vaccination strategies
Charlotte Martin (CHU St Pierre)
- 17.40 **Announcement of the winners of today's questionnaire in support of Be-R-Connected**
Catherine Bailleux, Association Manager & Jorien Geukens, Office & Project Assistant, KBVR-SRBR
- 17.45 **Closure of the Congress and Visit of the Exhibition**
Valérie Badot, President KBVR-SRBR

ePoster List

ePoster List

- YIM 1** Axial involvement in early peripheral spondyloarthritis: A prospective MRI study
Thomas Renson (UGent, VIB)
- YIM 2** Immunoglobulin G antibodies to three novel peptides in early axial spondyloarthritis in two independent cohorts
Pieter Ruytinx (UHasselt)
- YIM 3** Interleukin-23 inhibitors and their apparent ineffectiveness in the treatment of axial spondyloarthritis: A systematic review with metaanalysis
Louise Vanhoutte (KUL)
- YIM 4** Synovial tissue histopathology findings in early RA – Is it useful? Analysis of the Belgian CAP48 cohort
Stéphanie de Montjoye (UCL, IREC)
- YIM 5** Laser Speckle Contrast Analysis (LASCA) in rheumatoid arthritis
Michaël Vanden Bulcke (UGent)
- YIM 6** The FLARE-RA questionnaire can identify OMERACT flares in patients with rheumatoid arthritis included in the TapERA trial
Delphine Bertrand (KUL)
- YIM 7** May capillaroscopy be a candidate tool in future algorithms for SSsILD: Are we looking for the holy grail? A systematic review
Amber Vanhaecke (UGent)
- YIM 8** Epitope mapping of MDA5 using patient plasma derived autoantibodies
Eveline Van Gompel (Karolinska Institute, KUL)
- P1** Ultrasound as a diagnostic tool in giant cell arteritis - Experience from a Brussels hospital
Ioannis Raftakis (ULB)
- P2** Nailfold videocapillaroscopy: A diagnostic tool when clinical evaluation is misleading
Yora Mostmans (ULB)
- P3** Influence of extra-articular damage on use of biotherapies in patients with spondyloarthropathy: A retrospective study
Naiïla Senhaji (ULB)

ePoster List

- P4** Remission in axial spondyloarthritis: Is there a difference between NSAIDs and biologics in the real life?
Charlotte Baert (UCL)
- P5** Ixekizumab significantly improves patient-reported overall health as measured by SF-36 in patients with active ankylosing spondylitis/radiographic axial spondyloarthritis: 52-week results of two phase 3 trials
Filip Van den Bosch (UGent)
- P6** Patient-reported outcomes from a randomised, open-label, parallel-group study evaluating ixekizumab versus adalimumab in patients with PsA who are biologic DMARD naïve: 24-week results
Filip Van den Bosch (UGent)
- P7** Are axial spondyloarthritis patients diagnosed differently in an academic versus peripheral hospitals?
Ann-Sophie De Craemer (UGent)
- P9** Prevalence of clinical symptoms and laboratory markers in idiopathic inflammatory myopathies
Yves Piette (UGent)
- P10** SpA during the COVID-19 pandemic – Influence on patients' health perception
Sophie De Mits (UGent)
- P11** SpA during the COVID-19 pandemic – Chest expansion is the most affected clinical measurement
Sophie De Mits (UGent)
- P12** Secukinumab improves clinical and imaging outcomes in patients with Psoriatic Arthritis and axial manifestations with inadequate response to NSAIDs: Week 52 results from the MAXIMISE trial
Joëlle Margaux (ULB)
- P13** Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase III PREVENT study
Filip Van den Bosch (UGent)
- P14** Plasmocytosis and nephrotic syndrome revealing Sjögren's Syndrome
Céline La (ULB)

ePoster List

- P15** **Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment**
Joris Lenaerts (KUL)
- P16** **Nailfold capillaroscopy in Sjögren's Syndrome: A systematic literature review and standardised interpretation**
Karin Melsens (UGent)
- P17** **Magnetic resonance imaging of the sacroiliac joints in healthy subjects: Occurrence of inflammatory and structural lesions in relation to age**
Thomas Renson (UGent)
- P18** **Screening for immunoglobulin A antibody reactivity in early axial spondyloarthritis identifies novel antigenic targets**
Pieter Ruytinx (UHasselt)
- P19** **Fatigue and vitality but not disease outcomes strongly predict sensor-based physical activity behaviour in patients with axial spondyloarthritis**
Marlies Kaerts (KUL)
- P20** **Real-world efficacy and safety of Apremilast in Belgian patients with psoriatic arthritis: Final analysis of the multicentre, prospective APOLO study**
Kurt De Vlam (KUL)
- P21** **The impact of persistent inflammatory changes on prevalence of fat lesions in patients with axial spondyloarthritis treated with certolizumab pegol: 4-year MRI results from RAPID-axSpA**
Adrien Nzeusseu (UCL)
- P22** **Rheumatoid arthritis, Merkel cell carcinoma and checkpoints inhibitors: A case report**
Elena-Raluca Dragan (ULB)
- P23** **Reduction of complement serum levels in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibodies**
Tracy Vandergraesens (ULB)

ePoster List

- P24** **Otitis media as the presenting symptom in a patient with granulomatosis and vasculitis**
Ioannis Raftakis (ULB)
- P25** **Auto-immune or paraneoplastic myositis? A case report**
Carole Nagant (ULB)
- P26** **Pre-exposure prophylaxis with hydroxychloroquine does not prevent acquisition of SARS-CoV-2**
Héloïse Van Noten (ULB)
- P27** **The total FLARE-RA score is associated with flares three months later in patients with rheumatoid arthritis participating in the TapERA trial**
Delphine Bertrand (KUL)
- P28** **Barriers and facilitating factors of nurse led clinics for patients with rheumatoid arthritis**
Diederik De Cock (KUL)
- P29** **The ideal mhealth application for rheumatoid arthritis: Qualitative findings from stakeholder focus groups**
Diederik De Cock (KUL)
- P30** **The choice of bDMARD or tsDMARD therapy as first line therapy: Data of the TARDIS-RA registry, a nationwide Belgian biologic registry**
Diederik De Cock (KUL)
- P31** **A window of opportunity to lower fatigue complaints in patients with early rheumatoid arthritis: Data from the CareRA trial**
Diederik De Cock (KUL)
- P32** **Prospective non-interventional study to evaluate the use of glucocorticoids in combination with tocilizumab in patients with rheumatoid arthritis in Belgium: COGNOS**
Marie-Joëlle Kaiser (ULiège)
- P33** **Delayed recognition of lung involvement in Antisynthetase syndrome after seronegative polyarthritis onset: A case report**
Elke Decommer (VUB)
- P34** **Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: An updated integrated safety analysis**
Patrick Durez (UCL)

ePoster List

- P35** Herpes zoster infections in patients with inflammatory arthritis
Hannah Claus (UGent)
- P36** An unusual case of horizontal fracture of the lower endplate in a man with diffuse idiopathic skeletal hyperostosis
Abeline Kapuczinski (ULB)
- P37** An unusual case of spondylodiscitis and infectious sacroiliitis due to *Listeria monocytogenes*
Abeline Kapuczinski (ULB)
- P38** Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 52-week results
René Westhovens (KUL)
- P39** Efficacy and safety of filgotinib in methotrexate-naïve patients with RA: FINCH3 52-week results
René Westhovens (KUL)
- P40** Integrated safety analysis of filgotinib treatment for RA from seven clinical trials
Patrick Durez (UCL)
- P41** ReumaWerk!: Promoting professional reintegration of people with RMDs
Anja Marchal (ReumaNet)
- P42** Survey on the consultation profile of rheumatologists in Wallonia and Brussels for inflammatory joint diseases
Laurent Meric de Bellefon (UCL) - On Behalf of the Professional Association of Rheumatologists
- P43** Clinical treatment response still does not match patient reported improvement, even in early rheumatoid arthritis
Sofia Pazmino (KUL)
- P44** Granulomatosis with polyangiitis overlapping IgG4-related disease?
Aureliano Pistone (ULB)
- P45** Clinical course of COVID-19 infection in inflammatory rheumatologic patients: A monocentric Belgian experience
Aureliano Pistone (ULB)

ePoster List

- P46** A heterozygous mutation M694V in the MEFV gene and HLAB27 negative spondyloarthritis : The chicken egg paradox?
Julie Sarrand (ULB)
- P47** Should we use glucocorticoid in early rheumatoid arthritis? Results at 5 years from the ERA Louvain Brussels cohort
Emilie Sapart (UCL)
- P48** Ultrasound as an imaging biomarker of early response to tocilizumab and methotrexate in very early rheumatoid arthritis, TOVERA – A longitudinal study
Maria Stoenoiu (UCL)
- P49** Complete thoracolumbar spinal cord injury after minimal trauma in a patient with long-standing ankylosing spondylitis
Eugénie Van Mieghem (UA)
- P50** The use of mycophenolate in the treatment of corticosteroid resistant eosinophilic fasciitis - A case report
Steven Van Offel (UA)
- P51** Clinical case: Avascular necrosis of the foot and ankle in a patient with systemic sclerosis
Helene Wastyn (KUL)
- P52** Preliminary results of the Be-MULTRA study: Sonographic response to treatment with methotrexate in early rheumatoid arthritis
Ruth Wittoek (UGent)

Registration

Registration Fees

	Until 18 March
Members KBVR-SRBR	€ 75,00
Non Members	€ 95,00
Emeritus	€ 25,00
Trainees in Rheumatology*	€ 25,00

* Registration as a trainee or researcher non-MD will only be accepted if accompanied by a copy of your student card or a certificate of your director (proof to be uploaded during the registration process). Without proof the non-member fee will be charged.

The registration fee for participants includes

- Participation in all scientific sessions
- Participation in the 'Updates in Therapeutics' organised by the Industry
- Access to the virtual exhibition and ePosters
- Networking opportunities on the online platform

How to register

You can register online through the congress website www.rheumacongress.be. Click on 'Registration' for details and access to the online registration form. When your registration is completed successfully, you will receive an automatic confirmation. You can also print an invoice when you finalise your online registration.

Changes/Name Substitutions

You will receive a personal link in your final confirmation email. With this link it will be possible to make changes or transfer your registration to a colleague free of charge.

Cancellations

Participants canceling their registration before 1 March 2021, will receive a 50% refund. There will be no refunds for cancellations received after this date. Cancellations must be confirmed in writing to the Organising Secretariat. All refunds will be processed after the Congress.

Major Sponsors



Exhibitors



FRESENIUS
KABI
caring for life



janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson



MSD
INVENTING FOR LIFE

